Literature DB >> 29048973

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma.

Matteo S Carlino1, Shahneen Sandhu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29048973     DOI： 10.1200/JCO.2017.75.2055

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 2.  Immune Checkpoint Inhibitor Toxicity.

Authors:  David J Palmieri; Matteo S Carlino
Journal:  Curr Oncol Rep       Date:  2018-07-31       Impact factor: 5.945

3.  Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report.

Authors:  Manreet Randhawa; Gregory Gaughran; Christine Archer; Paul Pavli; Adrienne Morey; Sayed Ali; Desmond Yip
Journal:  World J Clin Oncol       Date:  2019-10-24

Review 4.  Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.

Authors:  Boris Shulgin; Yuri Kosinsky; Andrey Omelchenko; Lulu Chu; Ganesh Mugundu; Sergey Aksenov; Rodrigo Pimentel; Garrett DeYulia; Geoffrey Kim; Kirill Peskov; Gabriel Helmlinger
Journal:  Oncoimmunology       Date:  2020-05-21       Impact factor: 8.110
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.